efficacy of semaglutide and tirzepatide in reducing liver fat Evaluating the Cardiovascular Benefits Innovator 2.4 mg (Recombinant DNA (r-DNA)) Patients With Overweight or Obesity: A Critical Review of Current Evidence Tirzepatide for Weight Loss &

Celebrities like Andy Cohen are microdosing GLP-1s The Emmy-winning producer and Bravo TV host Andy Cohen recently revealed that he lost 25 pounds in about three months "microdosing a GLP-1 all summer." During his short-term usage of semaglutide (he didn't specify which GLP-1 he used), Cohen found it helped reduce his food cravings and reset his relationship with food

Budget 10-15% extra for waste

What the clinical trial data tells us about dose timing The pivotal SURMOUNT and SURPASS clinical trials that led to tirzepatide approval provide the best data on dosing consistency and outcomes

The most common adverse reactions reported in clinical trials were injection site reactions (erythema, pruritus, pain) occurring in approximately 8-13% of patients

The more clinically important question is how often this produces meaningful perioperative harm, which patients are at highest risk, and how clinicians should balance aspiration prevention against the metabolic, cardiovascular, logistical, and equity-related consequences of withholding therapy